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SUMMARY
Naltrexone is used as an off- label treatment in 
low doses for several chronic immune- modulated 
disorders in many countries. Although only small- scale 
clinical trials have been performed, these suggest 
efficacy in several diseases including Crohn’s disease, 
fibromyalgia and Gulf War Illness. Despite numerous 
internet reports of response to low- dose naltrexone 
(LDN), no clinical trials exist in people with chronic 
fatigue syndrome. This condition is characterised by 
chronic profound fatigue, postexertional malaise, pain 
and autonomic and neurocognitive disturbances. This 
series of three case reports compiled by people with 
long- term ill- health due to chronic fatigue syndrome 
shows the range of responses they observed when 
taking LDN, from life changing to a reduction in some 
symptoms only. Treatment doses ranged from 4 to 
12 mg. Clinical trials may be warranted to explore 
the potential use of naltrexone in people with these 
debilitating illnesses which currently have no licensed 
treatments available.
BACkgRoUnd
Chronic fatigue syndrome and myalgic encepha-
lomyelitis are chronic multisystem disorders char-
acterised by profound fatigue and postexertional 
malaise with multiple other symptoms varying 
among individuals, including widespread pain, 
immune dysfunction and autonomic and neuro-
cognitive symptoms.1 The annual incidence is 
around 15–26 per 100 000 persons,2 3 with a prev-
alence between 0.2% and 0.4%,4 5 depending on 
the exact definition used and the country of study. 
The level of disability is greater than for most other 
chronic illnesses, and full recovery is rare.6–8 Much 
is unknown about the illness and even the names 
ascribed are controversial.1
There is a systematic lack of funding of research 
and specialist services for people with these condi-
tions.9 10 Despite specialists, particularly in the USA, 
using a range of drugs in treatment,11 12 very few 
of these have been subjected to clinical trials, and 
the outcomes of the few that have been done have 
often been inconclusive.13 14 Reasons for failure to 
reach conclusions include difficulties in clinical trial 
design such as trials of short duration and small 
sample sizes; a lack of a single best clinical case defi-
nition and of a simple diagnostic marker1 and diffi-
culties in measuring outcomes (such as no way of 
measuring fatigue objectively). Many of these issues 
are associated with poor funding opportunities.15
Naltrexone is a safe synthetic antiopioid with 
widespread action at opioid and non- opioid 
receptors.16 It is currently licensed for treatments 
of alcoholism and opioid addiction at 50 mg. At 
lower doses, 3–4.5 mg, it appears to work as an 
immune modulator,17 and can also suppress tumour 
growth.18 19 This usage is commonly described as 
low- dose naltrexone (LDN).20 Small- scale clinical 
trials of LDN in multiple sclerosis, HIV, fibro-
myalgia, Gulf War Illness and Crohn’s disease 
have shown proof- of- concept efficacy and/or 
low toxicity.21–28 Recent before- and- after cohort 
studies of patients with Crohn’s disease and rheu-
matoid arthritis in Norway showed reductions in 
prescriptions for disease- modifying medications 
after starting LDN.29 30 We know of no clinical 
trials of naltrexone in patients with chronic fatigue 
syndrome or myalgic encephalomyelitis, although 
some patients report benefits.31 We present a series 
of three case reports of this treatment as a prelude, 
we hope, to future clinical trials. The reports were 
compiled by those people whose case histories are 
described, two of whom are coauthors, using historic 
diaries and previous medical records, including any 
objective measures that were available.
CASe pReSenTATion: CASe 1
A white British female, now aged 63 (the first 
author), developed viral meningitis with accom-
panying vomiting leading to severe dehydration 
in 1988 when aged 33. She had previously been 
well and working as a general practitioner. Viral 
meningitis was diagnosed by lumbar puncture and 
again 6 weeks later on repeat hospital admission. 
She remained extremely unwell, being bed bound 
and unable to self- care, with profound weak-
ness and fatigue, general malaise, light and sound 
sensitivity, repeated dizziness causing collapse, 
persistent anxiety and widespread pain. Although 
she improved slowly over the next 5 years, she was 
only able to return to work on a limited basis, still 
suffering headaches, fatigue, postexertional malaise 
and frequent migraine attacks characterised by 
vomiting and visual disturbances.
Following gastroenteritis in 1999, she again 
became bed bound and unable to self- care. Improve-
ment was slower than the initial illness, and after 5 
years she was still dependent on carers and used a 
motorised wheelchair when outside. She developed 
multiple food intolerances, shown on blood tests 
and confirmed by repeated withdrawals and rein-
troductions of intolerant foods. She showed a more 
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dramatic response to wheat, even small amounts, characterised 
by nausea, severe headache, rapid heart beat and collapse within 
10 min of consumption, followed by a week of reduced energy 
and absolute constipation.
inveSTigATionS: CASe 1
Extensive investigations were performed during several hospital 
admissions following the initial meningitis, including extensive 
screening for infections, brain scan and electroencephalogram. 
These were all normal, and she was diagnosed with chronic 
fatigue syndrome by the hospital clinician in 1989. This diag-
nosis was confirmed in 2001 and 2003 by a rheumatologist 
and a psychiatrist, respectively; in the latter case confirming 
the diagnosis by reference to the 1994 Centres for Disease 
Control criteria for chronic fatigue syndrome.32 In 2001, she 
was diagnosed by a clinical neuropsychologist as having cogni-
tive impairments characteristic of damage from viral meningitis. 
Although her IQ was in the very superior range, she was unable 
to complete the timed Stroop Neuropsychological screening test 
(less than second centile)33; the trail making test was below the 
25th percentile34 and the Ray complex figure was below the 
25th centile.35 These results showed respectively an inability 
to exclude irrelevant but superficially similar information, 
poor multitasking abilities and reduced visuospatial ability and 
memory. These results had improved only slightly by 2004, with 
further slight improvements by 2019; both the Ray complex 
figure and the Stroop test still scoring below the 25th centile for 
her age and educational level although the trail making test is 
now around the 50th centile.
An MRI scan of the brain in 1998 was normal, and an 
antigliadin antibody test for coeliac disease was negative in 
2002. In 2009, she was shown to be deficient in vitamin D 
(25- hydroxyvitamin D3 level of 22.7 nmol/L, current guidelines 
suggest above 50 nmol/L is sufficient).
TReATMenT: CASe 1
She tried various alternative treatments with little improvement. 
She improved slightly while taking antibiotic combinations 
including phenoxymethylpenicillin and azithromycin for a year 
in 2006 but relapsed rapidly on stopping them. She was started 
on oral vitamin D supplementation in 2009, although this did 
not improve her symptoms of fatigue. As she has had polymor-
phic light eruption since her midteens, she remains on colecal-
ciferol 20 000 IU every 2 weeks and now has normal vitamin D 
levels.
In 2010, she was prescribed LDN, initially at 1.5 mg, slowly 
increasing the dose over 2 years. She noticed slightly increased 
energy and reduced food intolerances while taking 4.5 mg/day 
but needed to reduce the dose to 3 mg due to increased head-
aches. Ten months later, she started increasing the dose again 
without recurrence of symptoms, and subsequent stepped dose 
increases coincided with further improvements in energy, mood 
and pain. At 9 mg, the frequent episodes of abdominal pain 
subsided, and she started eating a full diet, including wheat and 
dairy. Her prescribing doctor suggested experimenting to find 
the optimum dose of LDN, and after increasing to 7.5 mg two 
times per day, she settled on 6 mg two times per day, which she 
has taken for the past 7 years.
oUTCoMe And follow-Up: CASe 1
Now aged 63, 30 years after the initial meningitis, she currently 
has a normal quality of life with no signs of ill health, although 
energy levels can reduce slightly during infections, prolonged 
overexertion or excessive mental effort. Such reductions can be 
delayed up to 48 hours after the initial overstimulation, sugges-
tive of continuing mild postexertional malaise. Symptoms such 
as poor sleep and excessive pain are absent. Up until starting 
LDN, she was in receipt of the UK Government’s benefits of 
Disability Living Allowance at the higher rate for mobility 
(requiring the person to have severe walking difficulties) and 
middle rate for care (requiring frequent help during the day). 
These payments were reduced, and then finally stopped 3 years 
after starting LDN when it was clear she was stable and well, and 
could walk, and more recently, cycle, without problems. Prior 
to starting LDN, her intellectual and cognitive functioning was 
very limited. These abilities have returned apart from continuing 
cognitive impairments due to the meningitis.
CASe pReSenTATion: CASe 2
A previously well white female living in the USA, developed a 
sudden onset of ill health when 29 years old in 1989. Symp-
toms included profound fatigue and weakness, flu- like symp-
toms, postexertional malaise, cognitive impairment, nausea, 
widespread pain and sleep disturbance. Possible precipitating 
factors included possible viral infection, early pregnancy and 
exposure to ticks within 6 weeks of onset. She was diagnosed 
with chronic fatigue immune dysfunction syndrome by a 
neurologist after 2 years of ill health and this diagnosis, and/or 
myalgic encephalomyelitis has been reconfirmed several times 
since. During subsequent years, she continued with symptoms 
of postexertional neuroimmune exhaustion (as defined in the 
International Consensus Criteria for myalgic encephalomyelitis 
(2011)),36 pain, periodic muscle weakness, flu- like symptoms, 
orthostatic intolerance and unrefreshing sleep despite seeing 
many specialists.
TReATMenT: CASe 2
Many therapies have been tried, including antiviral agents for 
reactivated Epstein- Barr virus, with limited success.
She was prescribed LDN in 2014 when 54 years old. Due to 
known immune hypersensitivity (urticaria), the dose was started 
very low, at 0.25 mg/day, and increased very slowly over 4 years 
to the present dose of 4 mg. Initially, her sleep was disturbed 
by vivid dreaming. At about 6 months, when on 1 mg/day, 
she noticed improved sleep and lower pain levels, and these 
symptoms continued to improve as the naltrexone dosage was 
increased
oUTCoMe And follow-Up: CASe 2
Although pain and sleep issues continue, these are at a lower 
level than prior to starting naltrexone. Her sleep journal prior 
to starting LDN showed she awoke every 90 min through the 
night. Monitoring after starting LDN shows that although she 
may not sleep through, she does not have repeated awakenings. 
She no longer requires acupuncture for symptomatic pain relief. 
However, her functional level did not improve with LDN. Now 
aged 59, she also continues with other symptoms of myalgic 
encephalomyelitis including postexertional neuroimmune 
exhaustion, periodic muscle weakness, orthostatic intolerance, 
symptomatic sinus tachycardia, urticarial rashes and suscepti-
bility to bacterial infections. Due to these, she takes ivabradine 
2.5 mg two times per day and cetirizine 10 mg/day. Despite these 
continuing symptoms, she feels LDN is of sufficient benefit to 
continue long term.
CASe pReSenTATion: CASe 3
A white British male (the second author) sustained a head injury 
when 7 years old and was diagnosed with glandular fever when 
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patient’s perspective
Case 1
For me, low- dose naltrexone was truly life changing. From 
being virtually house bound, always limited by a multitude of 
symptoms, pain and low energy, I found my life returning. Every 
treatment or therapy I had tried previously involved effort—
pacing myself, training myself, coping with symptoms. With low- 
dose naltrexone, the improvement just happened—I didn’t have 
to try, I just got better. I went for walks and started cycling again. 
The first time I ate out when I was no longer limited by food 
allergies, I could select from the whole menu—the shock of all 
that choice! My husband commented I was no longer a shadow 
of a person but a genuine companion again. From being unable 
to string sentences together coherently for much of my adult life, 
I returned to university and gained a distinction in a Master of 
Research degree, when aged 62!
Case 2
After 25 years of living with the devastating effects of myalgic 
encephalomyelitis, I was struggling to cope with the limited 
options for symptom and pain management. Having had many 
bad reactions to medications, I was hesitant to try a medication 
that would affect my immune system so I started out at an 
extremely low dose and slowly increased dosage. While the 
dreaming was at times disturbing, the positive changes gave 
me a hope for improvement I had not had in many years. The 
subsequent improvements have led to a much higher quality 
of life and I would like to see this medication as an approved 
option for others in my situation.
Case 3
Since I was 14 (when I had my first chronic fatigue episode), 
whenever I have had any form of illness I have suffered from 
depressive episodes, including needing to withdraw socially 
and becoming very insular. This included the period prior to any 
illness, where I have felt run down or could tell a cold etc was 
forming. I started taking low- dose naltrexone when I was 37 and 
for the first time in 23 years, I have not had a depressive episode 
linked to colds or any other illness. Low- dose naltrexone has 
really helped improve my quality of life and also helped in social 
situations where I am not withdrawing and being insular like I 
had been previously.
learning points
 ► Naltrexone at low dose may work as an immune modulator, 
and small scale clinical trials in a range of conditions 
including fibromyalgia, Gulf War Illness and Crohn’s disease 
have shown efficacy and low toxicity.
 ► Although no clinical trials have been carried out, anecdotal 
web reports, and these three case studies suggest low- dose 
naltrexone may be helpful in at least some patients with 
chronic fatigue syndrome and myalgic encephalomyelitis.
 ► Clinical trials of off- patent drugs are difficult to fund. The 
lack of mechanisms for funding and licensing such drugs is 
a political issue which needs urgently addressing to save 
healthcare systems from ever- escalating drug costs.
10 years old. He developed severe tonsillitis in 1996 when 14 
years old. His symptoms gradually worsened and he became 
bedridden and unable to self- care, suffering profound fatigue, 
headaches, excessive day and night sleeping and light and sound 
sensitivity. He was diagnosed with chronic fatigue syndrome by 
a hospital paediatrician in 1997. He gradually improved over the 
next 3 years with increased energy. By his mid- 20s, he was able to 
work full time although with persistent tiredness and recurrent 
infections. He improved further by practising ‘pacing’, listening 
to body symptoms to control his activity and by changing jobs 
to one with flexible working hours, which he continues to this 
date. He continued to experience difficulty sleeping and recur-
rent colds, at least four per year, accompanied by energy dips 
and subsequent depression. He was diagnosed with nasal polyps, 
sinusitis and seasonal allergic rhinitis.
TReATMenT: CASe 3
In 2018, when aged 37, he started LDN, initially at 1 mg/day, 
increasing to 4.5 mg, which he still takes. He had no side effects 
starting the drug.
oUTCoMe And follow-Up: CASe 3
He noticed an improved sleep pattern, and now has fewer colds 
which are no longer associated with an energy dip or subse-
quent depression. Retrospective scoring of depression using the 
Hospital Anxiety and Depression Scale37 suggests his average 
mood improved from 13 (11–21 signifies depression) to 7 
(0–7 signifies no abnormality), his anxiety scores being normal 
throughout. His functional level improved from being mild–
moderately limited on a daily basis (60%–70% on a functional 
activity scale) to mild limitations (80%–90% on a functional 
activity scale38). The improvements are sufficiently marked that 
he intends to continue LDN long term.
For the past 4 years, he has followed a gluten and wheat- 
free diet and has been vegan for the past 18 months, partly due 
to cheese causing increased nasal symptoms. He has not tried 
altering his diet after starting naltrexone.
diSCUSSion
Given the widespread use of LDN in many countries, and the 
numerous internet reports, it is somewhat surprising that this is 
the first medical series of case reports of the effect of its use in 
people with chronic fatigue syndrome and myalgic encephalo-
myelitis. The mechanism of action for naltrexone at low dose in 
this disease group is unknown. It is possibly due to rebound of 
endorphins following short- term suppression or to direct action 
suppressing inflammation induced by microglia.39–41 There have 
been no formal dosing studies of naltrexone at low dose in any 
disorder. Therefore, although the dose of 3–4.5 mg is established 
in clinical practice, some practitioners use 9 mg (Klimas, personal 
communication, 2017) or higher42 in chronic fatigue syndrome. 
Causality and dosing need further study.
All case reports are limited by their lack of controlling for 
confounding factors and for possible placebo responses. 
Such factors can only be adequately controlled for within a 
randomised double- blind clinical trial. In the recent placebo- 
controlled, double- blind multicentre trial of rituximab in 
chronic fatigue syndrome, the placebo response rate was 35%.43 
Alternative explanations for improvements in these cases could 
also be due to fluctuations in the underlying disease, which can 
appear as temporary improvements and occasionally the disease 
improves spontaneously. However, all three subjects had tried 
alternative treatments without the long- term effects that LDN 
has produced, which in cases 2 and 3 were specific to particular 
symptoms. Although case 1 had noticed periods of moderately 
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improved health previously, these were limited in time, and her 
cognitive abilities had not previously improved. In addition, the 
initial improvements in symptoms with LDN were associated at 
each time point with an increase in dosage, and above 12 mg 
there was no further improvement, suggestive of a typical graded 
dose–response curve.
Internet reports suggest side effects can be troublesome 
initially, particularly increased fatigue and headaches.44 Two 
double- blind, placebo- controlled studies in people with fibro-
myalgia found no difference in tolerability between LDN and 
placebo but an increased frequency of vivid dreams and head-
aches.27 28 Recent work in Norway has found that individuals 
may experience fewer side effects if starting naltrexone at 6 mg, 
even if the final dose taken is lower than this (personal commu-
nication Brian Haviland 2018).
Not everyone with chronic fatigue syndrome or myalgic 
encephalomyelitis responds to naltrexone, although the exact 
proportion or the characteristics of those who do respond are 
not known. The three cases described here, compiled by three 
patients taking the drug, are typical of the range of responses 
in those who do respond, from a partial response through to 
life- changing differences. We recognise we had similar rapid 
onsets of illness, prolonged illnesses with limitation of life and 
curtailment of careers over many years and similar immune 
hyper- reactivity to external stimuli. Despite these similarities, it 
is not known whether we are describing particular characteristics 
which would make response to LDN more likely. The first and 
third case studies described reductions in symptoms of anxiety 
and depression, respectively, which therefore might originate 
from reduced neuroinflammation.45
These case studies are presented in the hope they will lead 
to randomised clinical studies defining the role and dose of 
naltrexone in treating people with chronic fatigue syndrome and 
myalgic encephalomyelitis compared with usual care or placebo. 
However, as naltrexone is out of patent, funding for such studies 
is problematic, despite the drug itself being relatively cheap. 
Most large studies are funded by large pharmaceutical compa-
nies, and there is no incentive for them to continue research of 
drugs once they are off- patent. However, we intend to replicate 
the approach of pharmaceutical companies by designing any 
clinical studies with licensing requirements in mind and will seek 
advice from the Medicines and Healthcare Products Regulatory 
Agency to this end.
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